section name header

Indications

High Alert


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: orthostatic hypotension

Derm: flushing, sweating

EENT: blurred vision, diplopia, miosis

Endo: adrenal insufficiency

GI: constipation, choking, dry mouth, GI obstruction, nausea, vomiting

GU: urinary retention

Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams

Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)

Misc: allodynia, opioid-induced hyperalgesia, physical dependence, psychological dependence, tolerance

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Hepatic Impairment

US Brand Names

OxyCONTIN, Roxicodone, Roxybond, Xtampza ER

Action

  • Binds to opiate receptors in the CNS.
  • Alters the perception of and response to painful stimuli, while producing generalized CNS depression.
Therapeutic effects:
  • Decreased pain.

Classifications

Therapeutic Classification: opioid analgesics

Pharmacologic Classification: opioid agonists, opioid agonists nonopioid analgesic combinations

Pharmacokinetics

Absorption: Well absorbed from the GI tract.

Distribution: Widely distributed to tissues.

Protein Binding: 38–45%

Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A4 isoenzyme and to a lesser extent by the CYP2D6 isoenzyme.

Half-Life: 2–3 hr.

Contr. Subst. Schedule

Schedule II (C-II)

Canadian Brand Names

Oxy IR, OxyNEO, Supeudol

Time/Action Profile

(analgesic effects)

ROUTEONSETPEAKDURATION
PO10–15 min60–90 min3–6 hr
PO-ER10–15 min3 hr12 hr

Extended release.



Patient/Family Teaching

Pronunciation

ox-i-KOE-done